Author | Study time | Any drug resistance% | INH% | RMP% | MDR-TB% | XDR-TB% |
---|---|---|---|---|---|---|
Demissie et al.[12] | 1994 | 15.6 | 8.4 | 1.8 | 1.2 | NR |
Abate et al.[13] | 1998 | 50 | 45 | 12 | 12 | NR |
Bruchfed et al.[14] | 1996-1997 | 14 | 8.3 | 2.5 | 0.8 | NR |
Gebeyehu et al.[15] | 2001 | 19.5 | 7.6 | 0 | 0 | NR |
Desta et al.[16] | 2004-2005 | 27.4 | 5.5 | 1.4 | 0 | NR |
Asmamaw et al.[17] | 2004-2005 | 21.4 | 13.3 | 1.2 | NR | NR |
Wright et al.[18] | 2002-2007 | 26.9 | 7.7 | 2.7 | 1.6 | NR |
Agonafir et al.[19] | 2005-2006 | 60.8 | 54.2 | 43.9 | 43 | 4.4 |
Hussen et al.[20] | 2011 | 36.3 | 29.4 | 13.7 | 11.8 | 1 |
Yimer et al.[21] | 2008 | 30.1 | 3.2 | 1 | 1 | NR |
Abate et al.[22] | 2004-2008 | 72.9 | 56.1 | 46.5 | 46.3 | NR |
Tessema et al.[23] | 2009 | 15.8 | 13.8 | 5.8 | 5 | NR |
Abebe et al.[24] | 2010-2011 | 18.4 | 13.2 | 2.2 | 1.5 | NR |
[Internet][25] | 2010-2011 | 31 | 26 | 12 | 9.7 | NR |
Biadglegne et al.[26] | 2012 | 6.7 | 3.6 | 1.8 | 1.3 | NR |
Esmael et al.[27] | 2010-2011 | 33.5 | 5.2 | 0.9 | 6.5 | NR |
Ejigu et al.[28] | 2005 | 0.0 | 55.2 | 32.8 | 32.8 | NR |
Demissie et al.[29] | 1998 | 12.9 | 8.4 | 0.6 | 0.6 | NR |
Wolde et al.[30] | 1986 | 15.2 | 12.0 | 1.1 | 3.3 | NR |